Navigation Links
Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
Date:7/14/2014

SAN DIEGO & BASKING RIDGE, N.J., July 14, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Regado Biosciences, Inc. (NASDAQ: RGDO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey.  The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between August 22, 2013 and July 9, 2014 (the "Class Period").  Regado is a biopharmaceutical company that focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.

Regado Is Accused of Misrepresenting Revolixys™ Kit Clinical Trail

According to the complaint, shares of Regado fell multiple times, beginning with an initial decline of $3.95 per share, or over 58%, to close at $2.81 on July 3, 2014 following an announcement by the company that it was voluntarily suspending the Phase 3 trial of its Revolixys™ Kit, known as REG1, an anticoagulant intended for use in patients with a wide variety of acute coronary syndromes, following a review of the Data Safety Monitoring Board to determine the safety and treatment benefit-risk ratio of the 3,234 patients enrolled in the study. Shortly thereafter, on July 9, 2014, Regado shares fell an addition $0.19 per share, or 7%, to close at $2.51 on July 10, 2014 following a subsequent announcement by the company that the U.S. Federal Drug Administration placed a hold on all patient enrollment and dosing in the Phase 3 trial of REG1. 

The complaint further alleges that Regado knew and failed to disclose that its REG1 Phase 3 trial patients were experiencing frequent and severe allergic reactions that would ultimately require the trial to be suspended.

Regado Investors Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo LLP

If you invested in Regado and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: https://www.robbinsarroyo.com/shareholders-rights-blog/regado-biosciences-inc/

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36754LOGO


'/>"/>
SOURCE Robbins Arroyo LLP
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Texas Medicaid Managed-Care Problems Gaining National Attention
3. Attention Veterans: New Medtech Job Training Program Accepting Applications through Friday, August 31
4. More than Morning Sickness: Kate Middletons Pregnancy Announcement Draws Attention to Rare Pregnancy Condition Known as Hyperemesis Gravidarum (HG)
5. GC-Rise Attracts Attention in Health Capital Market
6. Hepatitis Awareness: Bringing Attention to a Silent Epidemic
7. Attention Gates Foundation: Alsa Refinish Requests Your Help to Reduce Needle Use Worldwide
8. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
9. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
10. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
11. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/5/2017)... MANCHESTER, England , July 5, 2017 ... the perfect answer as physics and manufacturing combine to progress ... the thyroid, existing SPECT systems are unable to accurately quantify ... consequence, only limited information regarding the success of this radiotherapy ... ...
(Date:6/30/2017)... -- In vitro diagnostics market firm Kalorama Information has ... ten diagnostic companies have successfully completed financings.  The types ... loan facility.  The size of these financings ranged from ... provides a monthly IVD Market Trends Report ... "Diagnostics deals are ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 2017 , ... Fresh Wave® IAQ today announced the launch of its innovative ... universities at the APPA 2017 Annual Conference and Exhibition in Booth #414. ... without the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric ...
(Date:7/21/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has written a ... and pleads with world leaders to be more open about positive changes. Yisrayl says the ... there is a peaceful and positive way to solve all; yes, all issues, and he ...
(Date:7/21/2017)... ... ... West Dermatology is pleased to announce the newest addition to their Fresno, ... will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing with ... more. She graduated from the University of Florida College of Medicine Physician Assistant Program ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
(Date:7/20/2017)... ... July 20, 2017 , ... Remote Medical ... their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ Telepathology ... participants for real-time collaboration and immediate decision-making requirements. While never sharing IP ...
Breaking Medicine News(10 mins):